You are here: Industry Insights > Cell Therapy

News List

Key Considerations for Cold Chain Distribution in Cell Therapy Saher Haider
October 16, 2024
In this article, we focus on the key factors that influence cold chain distribution in cell therapy, including temperature stability, packaging and handling challenges, and compliance with regulatory standards.
Advancing Cryogenic Cold Chain Technology for Cell Therapy Products Saher Haider
October 15, 2024
Unlike conventional temperature-sensitive pharmaceutical products, cell therapy products have the most stringent requirements for cold chain logistics.In this article, we will dive deeper into cryogenic technology used at every step of the cold chain supp
Sartorius and TheWell Bioscience Partner to Enable More Accurate Predictions in Drug Discovery PharmaSources
April 10, 2024
TheWell Bioscience is a pioneer in the field of animal-free hydrogels and bioinks, critical components for the creation of 3D biomimicking platforms.
Research progress of dual-target CAR-T in China from the perspective of the ASCO 2023 Xiaobin/PharmaSources
June 27, 2023
At the ASCO this year, Gracell Bio announced the long-term follow-up data of its multi-center clinical study of CAR-T therapy with GC012F for recurrent/refractory multiple myeloma (R/R MM) in the form of oral report at the annual meeting.
NASDAQ Biopharma IPOs in the First Half of Q1 2022 David Orchard-Webb
March 01, 2022
So far in the first half of Q1 2022 seven biopharma companies have IPO’d on the NASDAQ.
Cell Therapy Expected to Treat Solid Tumors in the Future as a CAR-T cell Therapy Clinical Trial for Treating Gastric and Pancreatic Cancers was Accepted PharmaSources/Xiaobin
June 17, 2020
CAR-T cells can be easily led to cancer cells by relying on this target, to wipe out cancer. However, there is no such apparent target that only exists in tumor cells instead of normal cells in solid tumors.
T-CURX GmbH Announces Senior Leadership Appointments to Significantly Bolster Clinical Team PharmaSources
June 07, 2023
Appointments of co-founder Professor Michael Hudecek as Chief Medical Officer and Dr. Karl Schumacher as Chief Clinical Officer.
LIfT BioSciences and Minaris Regenerative Medicine Enter into a Development and Manufacturing Partnership for N-LIfT Allogeneic Neutrophil Based Cell Therapy PharmaSources
February 16, 2023
LIfT BioSciences and Minaris Regenerative Medicine GmbH have entered into a development and manufacturing partnership for N-LIfT, LIfT’s first-in-class neutrophil progenitor based Leukocyte Infusion Therapy.
Cryoport Partners with Cell Matters to Deliver Cryopreservation Services contractpharma
January 27, 2022
Further strengthens Cryport’s capabilities in the EMEA region.
Fujifilm Acquires Cell Therapy Mfg. Facility from Atara Biotherapeutics contractpharma
January 27, 2022
Expands its advanced therapies CDMO business .

Previous page 1 2 3 4 5 6 7 8 Next page